Short Interest in Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Grows By 613.1%

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) saw a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 625,772 shares, an increase of 613.1% from the May 14th total of 87,758 shares. Approximately 3.5% of the company’s shares are sold short. Based on an average daily volume of 38,097,719 shares, the days-to-cover ratio is presently 0.0 days.

Jupiter Neurosciences Stock Down 2.9%

NASDAQ:JUNS traded down $0.01 on Wednesday, reaching $0.23. 1,896,991 shares of the company’s stock were exchanged, compared to its average volume of 3,593,414. The firm has a market capitalization of $8.16 million, a price-to-earnings ratio of -0.83 and a beta of 1.71. The business has a fifty day moving average of $0.33 and a 200-day moving average of $0.64. Jupiter Neurosciences has a 52-week low of $0.17 and a 52-week high of $3.33.

Jupiter Neurosciences (NASDAQ:JUNS) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.23 million.

Institutional Trading of Jupiter Neurosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC increased its stake in Jupiter Neurosciences by 27.8% during the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after purchasing an additional 28,826 shares during the period. Allen Capital Group LLC purchased a new stake in Jupiter Neurosciences during the fourth quarter worth about $31,000. Yorkville Advisors Global LP purchased a new stake in Jupiter Neurosciences during the fourth quarter worth about $135,000. Finally, Vestor Capital LLC increased its stake in Jupiter Neurosciences by 144,607.2% during the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock worth $365,000 after purchasing an additional 970,314 shares during the period.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research note on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.